Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asif Serajian

Cardiovascular Disease Elmhurst, IL Doctor of Osteopathy

NPI 1790897049 CMS profile 354357

340 W Butterfield Rd Ste 3A, Elmhurst, IL 60126

Open in the dashboard

General payments

$21,874

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asif Serajian of Elmhurst, IL is reported in the CMS Open Payments database as having received $21,874 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,722 80
2024 General $2,643 75
2023 General $3,253 61
2022 General $1,378 29
2021 General $1,831 11
2020 General $1,727 7
2019 General $9,321 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asif Serajian
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Asif Serajian were reported at $1,722. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Asif Serajian Cardiovascular Disease median Middle half National median
2019 $9,321 $450 $127–$1,392 $163
2020 $1,727 $242 $77–$751 $114
2021 $1,831 $335 $101–$1,037 $132
2022 $1,378 $395 $121–$1,211 $149
2023 $3,253 $443 $136–$1,283 $160
2024 $2,643 $450 $136–$1,323 $164
2025 $1,722 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13,729 31 payments
  2. Medtronic, Inc. $943 9 payments
  3. Biotronik Inc. $932 12 payments
  4. Novartis Pharmaceuticals Corporation $781 39 payments
  5. Merck Sharp & Dohme Corporation $641 30 payments
  6. Janssen Pharmaceuticals, Inc $639 20 payments
  7. Abbott Laboratories $606 9 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $497 20 payments
  9. AstraZeneca Pharmaceuticals LP $424 19 payments
  10. Amgen Inc. $357 18 payments
  11. Other $2,325 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,750 9 payments
  2. Food and Beverage $8,358 281 payments
  3. Travel and Lodging $701 4 payments
  4. Education $65 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $13,729 31 payments
  2. Micra $870 5 payments
  3. VERQUVO $843 40 payments
  4. LEQVIO $530 27 payments
  5. FARXIGA $394 17 payments
  6. OPSUMIT $357 8 payments
  7. XARELTO $343 9 payments
  8. JARDIANCE $320 14 payments
  9. Impella $308 8 payments
  10. Repatha $266 14 payments
  11. Other $5,215 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

7,771

Median for Cardiology: 2,533

Drug cost

$2,014,321

Median for Cardiology: $485,213

Branded share of claims

29.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 418 $554,575
Opsumit Macitentan Brand 15 $296,400
Entresto Sacubitril/Valsartan Brand 196 $263,315
Farxiga Dapagliflozin Propanediol Brand 274 $260,092
Jardiance Empagliflozin Brand 143 $170,821
Xarelto Rivaroxaban Brand 133 $150,473
Camzyos Mavacamten Brand 11 $90,900
Inpefa Sotagliflozin Brand 50 $47,515
Multaq Dronedarone Hcl Brand 15 $31,465
Repatha Sureclick Evolocumab Brand 29 $22,633

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$553,305

Of which drugs: $994

Medicare patients

1,758

Average age 77

Services billed

7,269

938 women, 820 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 54%
Heart failure 51%
Diabetes 46%
Chronic kidney disease 40%
Atrial fibrillation 37%
Depression 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 39 160 $994

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $225
$225 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $196
$196 274 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $148
$148 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $137
$137 — —
Repatha
  • Amgen Inc. $123
$123 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record